(Reuters) -Regeneron Pharmaceuticals Inc’s said on Thursday its third-quarter profit nearly doubled, boosted by strong sales of its drugs, including the COVID-19 antibody cocktail.
The company’s net profit rose to $1.63 billion, or $14.33 per share, in the quarter ended Sept. 30, from $842.1 million, or $7.39 per share, a year earlier.
Revenue jumped 51% to $3.45 billion, including $804 million attributable to its antibody cocktail, REGEN-COV.
The company got a fresh order from the U.S. government in September for 1.4 million additional doses of REGEN-COV worth $2.94 billion, after it completed supplying 1.5 million doses in the second quarter. Regeneron will supply the additional doses by Jan. 31.
During the third quarter, a sharp surge in COVID-19 cases led by the Delta variant caused a “tremendous acceleration” in use of the cocktail, Leonard Schleifer, chief executive officer of Regeneron, had said in August.
(Reporting by Dania Nadeem and Leroy Leo in Bengaluru; Editing by Maju Samuel)
